Advertisement
Screener

GENZYME CORP Patents: Applications Rejected

GENZYME CORP Patent Applications Rejected

37 applications abandoned without a patent; the status gives the reason, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.

  • 2024-04-16: Application 18637271; Invention OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF; Applicant Genzyme Corporation; Status Abandoned -- Incomplete Application (Pre-examination).
  • 2024-01-10: Application 18409535; Invention TREATMENT OF ABNORMAL BONE CONDITIONS IN ACID SPHINGOMYELINASE DEFICIENCY PATIENTS; Applicant Genzyme Corporation; Status Abandoned -- Failure to Respond to an Office Action.
  • 2023-11-02: Application 18500926; Invention METHODS FOR PURIFICATION OF RECOMBINANT AAV VECTORS; Applicant Genzyme Corporation; Status Abandoned -- Failure to Respond to an Office Action.
  • 2023-10-17: Application 18488346; Invention Gene Therapy For Neurodegenerative Disorders; Applicant Genzyme Corporation; Status Abandoned -- Failure to Respond to an Office Action.
FiledApplicationInventionApplicantStatusPublished asInventor nameInventor countryExaminer
2024-04-1618637271OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOFGenzyme CorporationAbandoned -- Incomplete Application (Pre-examination)
Yunxiang ZHU
Seng H. Cheng
Canwen Jiang
Luis Z. Avila
United States
United States
United States
United States
2024-01-1018409535TREATMENT OF ABNORMAL BONE CONDITIONS IN ACID SPHINGOMYELINASE DEFICIENCY PATIENTSGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20240218338A1
Ana Cristina SCHEIDT-PUGA
France
LEE, JAE W
2023-11-0218500926METHODS FOR PURIFICATION OF RECOMBINANT AAV VECTORSGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20240287467A1
Paulene McLean Quigley SHELDON
Peter S. GAGNON
Gina NICHOLS
Barbara A. THORNE
United States
United States
United States
United States
BLUMEL, BENJAMIN P
2023-10-1718488346Gene Therapy For Neurodegenerative DisordersGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20240033323A1
Marco A. PASSINI
Lamya Shihabuddin
Seng H. Cheng
United States
United States
United States
GRABER, JAMES J
2023-10-1118379110OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOFGenzyme CorporationAbandoned -- Incomplete Application (Pre-examination)
Yunxiang ZHU
Seng H. CHENG
Canwen JIANG
Luis Z. AVILA
United States
United States
United States
United States
2023-08-2218236462METHODS FOR TREATING RECEPTOR-INTERACTING PROTEIN KINASE 1-MEDIATED DISEASESGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20240100065A1
Nazem Atassi
Catherine Cantalloube
Agnès Hincelin-Mery
Donato Teutonico
United States
France
France
France
HAVLIN, ROBERT H
2023-08-0818231628ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOFGENZYME CORPORATIONAbandoned -- Failure to Respond to an Office ActionUS20240109882A1
Elisabeth DEFOSSA
Uwe HEINELT
Hans MATTER
Maria MENDEZ-PEREZ
Nils RACKELMANN
Kurt RITTER
Hauke SZILLAT
Gernot ZECH
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
HABTE, KAHSAY
2023-05-1018315332EARLY POST-TRANSFECTION ISOLATION OF CELLS (EPIC) FOR BIOLOGICS PRODUCTIONGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20240026410A1
Victor R. Cairns
Christine DeMaria
Jason Vitko
United States
United States
United States
HIBBERT, CATHERINE S
2023-04-2118304519Compositions and Methods for Treating Spinal Muscular AtrophyGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20240000886A1
Marco A. Passini
Lamya S. Shihabuddin
Catherine R. O'Riordan
Seng H. Cheng
United States
United States
United States
United States
POLIAKOVA-GEORGAN, EKATERINA
2023-03-0818119201GENE THERAPY FOR NIEMANN-PICK DISEASE TYPE AGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20230287366A1
Marco A. PASSINI
Robin J. ZIEGLER
James C. DODGE
Lamya SHIHABUDDIN
Seng H. CHENG
United States
United States
United States
United States
United States
HILL, KEVIN KAI
2023-03-0718118549Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolineGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20240150317A1
Jorgen Blixt
Michael David Golden
Philip John Hogan
David Michael Glanville Martin
Francis Joseph Montgomery
Zakariya Patel
John David Pittam
George Joseph Sependa
Christopher John Squire
Nicholas Cartwright Alexander Wright
Sweden
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
WARD, PAUL V
2022-12-1418066175METHODS TO PRODUCE ROD-DERIVED CONE VIABILITY FACTOR (RDCVF)Genzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20230322873A1
Catherine R. O'RIORDAN
William H. BRONDYK
United States
United States
BURKHART, MICHAEL D
2022-12-1418066149GENE THERAPY FOR AMYOTROPHIC LATERAL SCLEROSIS AND OTHER SPINAL CORD DISORDERSGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20230364200A1
James Dodge
Lamya Shihabuddin
Catherine O'Riordan
United States
United States
United States
KELLY, ROBERT M
2022-09-0917930867Treatment of Multiple Sclerosis with Anti-CD52 AntibodiesGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20230167189A1
David H. MARGOLIN
United States
JOHANSEN, PETER N.
2022-08-0117878884METHODS AND COMPOSITIONS FOR TREATING A BLEEDING EVENT IN A SUBJECT HAVING HEMOPHILIAGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20230158058A1
Akin Akinc
United States
WHITEMAN, BRIAN A
2022-05-2317751433THYROID STIMULATING HORMONE COMPOSITIONSGENZYME CORPORATIONAbandoned -- Failure to Respond to an Office ActionUS20230126645A1
Clark PAN
Huawei QIU
Sunghae PARK
United States
United States
United States
DEBERRY, REGINA M
2022-03-0317686245USE OF iNOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTUREGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20220340883A1
Peter PECHAN
Jeffery ARDINGER
Abraham SCARIA
Samuel WADSWORTH
United States
United States
United States
United States
POPA, ILEANA
2022-02-1817675474DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINGOMYELINASE DEFICIENCYGENZYME CORPORATION
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Abandoned -- Failure to Respond to an Office ActionUS20220305091A1
Edward H. Schuchman
Robert J. Desnick
Gerald F. Cox
Laura P. Andrews
James M. Murray
United States
United States
United States
United States
United States
CRUM, MARY ABOU NADER
2022-02-0917668209COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORSGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20220396588A1
John L. Kane JR.
Claude Barberis
Mark Czekaj
Paul Erdman
Barret Giese
Michael Kothe
Tieu-Binh Le
Jinyu Liu
Liang Ma
Markus Metz
Vinod Patel
Andrew Scholte
Patrick Shum
Linli Wei
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
RODRIGUEZ-GARCIA, VALERIE
2022-01-1917579281METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDSGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20220364111A1
Guang QU
John Fraser WRIGHT
United States
United States
LI, BAO Q
2022-01-1317574674CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACYGENZYME CORPORATIONAbandoned -- Failure to Respond to an Office ActionUS20220409589A1
Gary J. Bridger
Renato T. Skerlj
Al Kaller
Curtis Harwig
David Bogucki
Trevor R. Wilson
Jason B. Crawford
Ernest J. McEachern
Bem Atsma
Siqiao Nan
Yuanxi Zhou
Dominique Schols
Christopher Dennis Smith
Maria Rosaria Di Fluri
United States
United States
Canada
Canada
Canada
Canada
Canada
Canada
Canada
China
Canada
Belgium
Canada
Canada
NORTHINGTON DAVIS, ZINNA
2022-01-1017572330SLOW INTRAVENTRICULAR DELIVERYGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20220370348A1
James C. DODGE
Marco A. PASSINI
Lamya S. SHIHABUDDIN
Seng H. CHENG
United States
United States
United States
United States
LANKFORD JR, LEON B
2021-09-2217482193Recombinant Glycoproteins and Uses ThereofGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20220064617A1
Karen Lee
Christopher Hwang
Christine DeMaria
United States
United States
United States
RAMIREZ, DELIA M
2021-09-1017472367OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOFGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20220204963A1
Yunxiang ZHU
Seng H. CHENG
Canwen JIANG
Luis Z. AVILA
United States
United States
United States
United States
BERRY, LAYLA D
2021-09-0317465994INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASEGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20210393590A1
Hanlan LIU
Chris WILLIS
Renu BHARDWAJ
Diane P. COPELAND
Abizer HARIANAWALA
Jeffrey SKELL
John MARSHALL
Jianmei KOCHLING
Gerard PALACE
Judith PETERSCHMITT
Craig SIEGEL
Seng CHENG
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
HAVLIN, ROBERT H
2021-07-1417422982SERPINC1 iRNA Compositions and Methods of Use ThereofGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20220079971A1
Akin Akinc
United States
TRAN, CHRISTINA L
2021-07-0217367027FUSION PROTEINS COMPRISING PDGF AND VEGF BINDING PORTIONS AND METHODS OF USING THEREOFGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20220064262A1
Peter PECHAN
Jeffery ARDINGER
Hillard RUBIN
Samuel WADSWORTH
Abraham SCARIA
United States
United States
United States
United States
United States
MOLOYE, TITILAYO
2021-06-2317356176AAV VIRIONS WITH DECREASED IMMUNOREACTIVITY AND USES THEREFORGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20220016264A1
Alejandra E. ARBETMAN
Peter C. COLOSI
Michael A. LOCHRIE
Richard T. SUROSKY
United States
United States
United States
United States
BLUMEL, BENJAMIN P
2021-06-2217354818METHODS AND COMPOSITIONS FOR TREATING HEMOPHILIAGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20210393669A1
Baisong Mei
Shauna Andersson
Qifeng Yu
Pronabesh DasMahapatra
United States
United States
United States
United States
ZARA, JANE J
2021-05-1417321128Methods and Systems for Processing a Cell CultureGenzyme CorporationAbandoned -- After Examiner's Answer or Board of Appeals DecisionUS20210269477A1
Konstantin Konstantinov
Benjamin Wright
Jin Yin
Marcella Yu
Hang Zhou
United States
United States
United States
United States
China
MENON, KRISHNAN S
2021-04-2717242016GLUCOSYLCERAMIDE SYNTHASE INHIBITORSGENZYME CORPORATIONAbandoned -- Failure to Respond to an Office ActionUS20210261557A1
Elyse BOURQUE
Mario CABRERA-SALAZAR
Cassandra CELATKA
Seng CHENG
Mary A. CROMWELL
Andrew GOOD
Bradford HIRTH
Katherine JANCSICS
John P. LEONARD
Lingyun LI
James LILLIE
Hanlan LIU
Elina MAKINO
John MARSHALL
Paul MASON
Markus METZ
Fazeela MORSHED
Thomas O'SHEA
Ronald SCHEULE
Renato SKERLJ
Bing WANG
Yibin XIANG
Zhong ZHAO
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
RAMACHANDRAN, UMAMAHESWARI
2021-02-2617187409METHODS FOR PREVENTING RETROPULSION OF CONCRETIONS AND FRAGMENTS DURING LITHOTRIPSYGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20210353301A1
Jean-Marie Vogel
James A. Wilkie
United States
United States
HOUGH, JESSANDRA F
2021-01-2917162541OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOFGenzyme CorporationAbandoned -- Incomplete Application (Pre-examination)
Yunxiang ZHU
Seng H. CHENG
Canwen JIANG
Luis Z. AVILA
United States
United States
United States
United States
2021-01-1517150856Quinazoline Derivatives as VEGF InhibitorsGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20210276972A1
Andrew Peter Thomas
Elaine Sophie Elizabeth Stokes
Laurent Francois Andre Hennequin
United Kingdom
United Kingdom
France
WARD, PAUL V
2021-01-0717143821INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASEGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20210369672A1
Hanlan LIU
Chris WILLIS
Renu BHARDWAJ
Diane P. COPELAND
Abizer HARIANAWALA
Jeffrey SKELL
John MARSHALL
Jianmei KOCHLING
Gerard PALACE
Judith PETERSCHMITT
Craig SIEGEL
Seng CHENG
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
CALAMITA, HEATHER
2019-05-0316403161Perfusion Bioreactor With Filtration SystemsGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20190338238A1
Jiuyi Lu
Jason Walther
Jonathan Wang
Kevin Victor Chen
United States
United States
United States
United States
DRODGE, JOSEPH W
2017-08-0915549962ENHANCED DELIVERY OF VIRAL PARTICLES TO THE STRIATUM AND CORTEXGenzyme CorporationAbandoned -- Failure to Respond to an Office ActionUS20190111157A1
Lisa M. STANEK
Lamya SHIHABUDDIN
United States
United States
NICOL, ALEXANDER W